{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:31:30Z","timestamp":1767339090824},"reference-count":41,"publisher":"Wiley","issue":"s66","license":[{"start":{"date-parts":[[2005,6,6]],"date-time":"2005-06-06T00:00:00Z","timestamp":1118016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Despite the great progress that has been made over the last several decades in the treatment of lymphoma, the prognosis for patients with relapsed disease, and particular sub\u2010types of lymphoma like mantle cell and T cell lymphoma, remains quite poor. While major advances in the use of combination chemotherapy, monoclonal antibodies, peripheral blood stem cell transplants, and radioimmunotherapy, have provided new opportunities to alter the natural history of these diseases, and even improve cure rates among elected sub\u2010populations of patients, these \u2018traditional\u2018 approaches have not benefited all patients, or sub\u2010types of lymphoma. The incredibly rapid pace of understanding the molecular basis for the discrete sub\u2010types of both non\u2010Hodgkin's lymphoma and Hodgkin's Disease is beginning to afford exciting new opportunities to both risk stratify patients, and to identify potentially novel \u2018drugable\u2019 targets. These advancements in understanding the major molecular defects in lymphoma, have provided a new context in which we can rethink the use of new and old drugs, and design new ones with unique mechanisms of action. The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly daunting. A plethora of new small molecules that target bcl\u20102, mTOR, histone deactylases, and NF\u2010kB have shown promising preclinical activity, and are now promising early phase activity. In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other \u2018rational\u2019 target based approach. In addition, beyond the novel small molecules affecting unique and heretofore unrecognized biological pathways, there continues to be a robust and important effort to identify new derivatives of older generation drugs with hopefully better activity, and less toxicity. For example, new generation anthracenediones and anti\u2010folates, and new formations of older drugs like doxorubicin, irinotecan, and vincristine afford new opportunities to favourably change the pharmacokinetic profile of these agents, and improve their overall safety profile. While it would not be possible to address each and every new such drug, we hope to touch on some of the major new themes and agents emerging for the treatment of Hodgkin's Disease and non\u2010Hodgkin's lymphoma.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00470.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T01:46:45Z","timestamp":1279417605000},"page":"150-158","source":"Crossref","is-referenced-by-count":20,"title":["Developing new drugs for the treatment of lymphoma"],"prefix":"10.1111","volume":"75","author":[{"given":"Owen A.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.7.3107"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.3.1365"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.4.1783"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)43856-8"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.2.761"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0021-9258(19)69833-9","article-title":"Identification of the active amino acid residue of the polypeptide of ATP\u2010dependent protein breakdown","volume":"256","author":"Hershko A","year":"1981","journal-title":"J Biol Chem"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90396-4"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15671"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.10.110194.002201"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.649"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2798"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.10.110194.002201"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10876"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3130"},{"key":"e_1_2_7_16_2","first-page":"2638","article-title":"Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease","volume":"104","author":"Younes A","year":"2004","journal-title":"Am Soc Hematol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_7_18_2","article-title":"A multicenter Experience with Single Agent Bortezomib in Non\u2010Hodgkin's Lymphoma Reveals Marked Difference in Sub\u2010Type Sensitivity to Proteasome Inhibition","volume":"104","author":"O'Connor O","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1386.1386","article-title":"clinical study of bortezomib (VELCADE) in patients (pts) with relapsed\/refractoryy non\u2010Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)","volume":"104","author":"Strauss S","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.608.608","article-title":"trial of bortezomib in mantle cell lymphoma","volume":"104","author":"Belch A","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1210"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.12.1695"},{"key":"e_1_2_7_24_2","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly WK","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3003"},{"key":"e_1_2_7_26_2","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler LM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.5.599"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/43710"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/38664"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80078-9"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"e_1_2_7_32_2","article-title":"Depsipeptide (FK228) in patients with cutaneous t cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy","volume":"102","author":"Piekarz RL","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_33_2","article-title":"Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T\u2010cell lymphoma (CTCL) and peripheral T\u2010cell lymphoma (PTCL)","volume":"102","author":"Duvic M","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-6-785"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401328"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2302::AID-CNCR18>3.0.CO;2-0"},{"key":"e_1_2_7_39_2","first-page":"351","article-title":"Biochemical and pharmacologic properties of a new folate analog, 10\u2010deaza\u2010aminopterin, in mice","volume":"66","author":"Sirotnak FM","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077124"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255903"},{"key":"e_1_2_7_42_2","unstructured":"TonerLVR SmithE GardnerJ HeaneyM Teruya\u2010FeldsteinJ SirotnakF O'ConnorO.The schedule dependent effects of the novel antifolate 10\u2010propargyl\u201010dezaminopterin (PDX) and gemcitabine are markedly superior to methotrexate and cytarabine in models of human non\u2010Hodgkin's lymphoma. Sumbitted."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00470.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00470.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:24:38Z","timestamp":1695716678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00470.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,6]]},"references-count":41,"journal-issue":{"issue":"s66","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00470.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00470.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,6]]}}}